
Marie Wahren-Herlenius

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2833436/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immunopathogenic mechanisms of systemic autoimmune disease. Lancet, The, 2013, 382, 819-831.	6.3	446
2	Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. Nature Genetics, 2013, 45, 1284-1292.	9.4	427
3	Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with SjĶgren's syndrome. Arthritis and Rheumatism, 2003, 48, 3187-3201.	6.7	391
4	Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23–Th17 pathway. Journal of Experimental Medicine, 2009, 206, 1661-1671.	4.2	259
5	Induction of interferon-α by immune complexes or liposomes containing systemic lupus erythematosus autoantigen– and Sj¶gren's syndrome autoantigen–associated RNA. Arthritis and Rheumatism, 2006, 54, 1917-1927.	6.7	218
6	Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52-kd antibodies. Arthritis and Rheumatism, 2004, 50, 1253-1261.	6.7	210
7	State of the art: Reproduction and pregnancy in rheumatic diseases. Autoimmunity Reviews, 2015, 14, 376-386.	2.5	169
8	Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Research and Therapy, 2006, 8, R167.	1.6	162
9	Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in salivary glands from patients with Sj�gren's syndrome. Arthritis and Rheumatism, 1998, 41, 2238-2248.	6.7	154
10	Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. Journal of Experimental Medicine, 2005, 201, 11-17.	4.2	151
11	The Sjol`gren's Syndrome-Associated Autoantigen Ro52 Is an E3 Ligase That Regulates Proliferation and Cell Death. Journal of Immunology, 2006, 176, 6277-6285.	0.4	151
12	Expression of the B Cell-Attracting Chemokine CXCL13 in the Target Organ and Autoantibody Production in Ectopic Lymphoid Tissue in the Chronic Inflammatory Disease Sjögren's Syndrome. Scandinavian Journal of Immunology, 2002, 55, 336-342.	1.3	150
13	Mutations in the gene encoding fibroblast growth factor 10 are associated with aplasia of lacrimal and salivary glands. Nature Genetics, 2005, 37, 125-128.	9.4	144
14	The complexity of Sjögren's syndrome: Novel aspects on pathogenesis. Immunology Letters, 2011, 141, 1-9.	1.1	144
15	The immunobiology of Ro52 (TRIM21) in autoimmunity: A critical review. Journal of Autoimmunity, 2012, 39, 77-82.	3.0	142
16	Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis and Rheumatism, 2005, 52, 3639-3645.	6.7	137
17	A serologic marker for fetal risk of congenital heart block. Arthritis and Rheumatism, 2002, 46, 1233-1241.	6.7	135
18	Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. Annals of the Rheumatic Diseases, 2017, 76, 1042-1050.	0.5	132

#	Article	IF	CITATIONS
19	Self Protection from Anti-Viral Responses – Ro52 Promotes Degradation of the Transcription Factor IRF7 Downstream of the Viral Toll-Like Receptors. PLoS ONE, 2010, 5, e11776.	1.1	115
20	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and SjĶgren's Syndrome. Arthritis and Rheumatology, 2016, 68, 1290-1300.	2.9	114
21	Association of EBF1, FAM167A(C8orf13)-BLK and TNFSF4 gene variants with primary Sjögren's syndrome. Genes and Immunity, 2011, 12, 100-109.	2.2	113
22	Interferon-Î \pm Induces Up-regulation and Nuclear Translocation of the Ro52 Autoantigen as Detected by a Panel of Novel Ro52-specific Monoclonal Antibodies. Journal of Clinical Immunology, 2008, 28, 220-231.	2.0	103
23	NCR3/NKp30 Contributes to Pathogenesis in Primary Sjögren's Syndrome. Science Translational Medicine, 2013, 5, 195ra96.	5.8	99
24	Mechanisms in fetal bradyarrhythmia: 65 cases in a single center analyzed by Doppler flow echocardiographic techniques. Ultrasound in Obstetrics and Gynecology, 2011, 37, 172-178.	0.9	84
25	Congenital heart block: evidence for a pathogenic role of maternal autoantibodies. Arthritis Research and Therapy, 2012, 14, 208.	1.6	82
26	The Expression of BAFF Is Controlled by IRF Transcription Factors. Journal of Immunology, 2016, 196, 91-96.	0.4	78
27	Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus. Lupus, 2007, 16, 794-802.	0.8	75
28	The IRF5–TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. Human Molecular Genetics, 2015, 24, 582-596.	1.4	74
29	Increased Frequency of Cells Secreting Interleukin-6 and Interleukin-10 in Peripheral Blood of Patients with Primary Sjogren's Syndrome. Scandinavian Journal of Immunology, 1999, 49, 533-538.	1.3	73
30	Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjögren's syndrome. Arthritis and Rheumatism, 2006, 54, 2289-2294.	6.7	73
31	Transcription profiling of peripheral B cells in antibodyâ€positive primary Sjögren's syndrome reveals upregulated expression of <i>CX3CR1</i> and a type I and type II interferon signature. Scandinavian Journal of Immunology, 2018, 87, e12662.	1.3	72
32	An update on the role of type I interferons in systemic lupus erythematosus and Sjögren's syndrome. Current Opinion in Rheumatology, 2018, 30, 471-481.	2.0	70
33	Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome. Clinical Immunology, 2016, 168, 25-29.	1.4	68
34	<scp>IL</scp> â€17: A new actor in <scp>IFN</scp> â€driven systemic autoimmune diseases. European Journal of Immunology, 2012, 42, 2274-2284.	1.6	65
35	Molecular mechanisms of congenital heart block. Experimental Cell Research, 2014, 325, 2-9.	1.2	65
36	Anti-Ro52 Autoantibodies from Patients with Sjögren's Syndrome Inhibit the Ro52 E3 Ligase Activity by Blocking the E3/E2 Interface. Journal of Biological Chemistry, 2011, 286, 36478-36491.	1.6	64

#	Article	IF	CITATIONS
37	Pathogenesis of the Novel Autoimmune-Associated Long-QT Syndrome. Circulation, 2015, 132, 230-240.	1.6	62
38	Development of heart block in children of SSA/SSB-autoantibody-positive women is associated with maternal age and displays a season-of-birth pattern. Annals of the Rheumatic Diseases, 2012, 71, 334-340.	0.5	60
39	Update on the immunobiology of Sjögren's syndrome. Current Opinion in Rheumatology, 2015, 27, 468-475.	2.0	60
40	Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons. PLoS Genetics, 2017, 13, e1006820.	1.5	60
41	Antibodies to amino acid 200–239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block. Clinical and Experimental Immunology, 2008, 154, 30-37.	1.1	59
42	Incident cases of primary Sjögren's syndrome during a 5-year period in Stockholm County: a descriptive study of the patients and their characteristics. Scandinavian Journal of Rheumatology, 2015, 44, 135-142.	0.6	59
43	Augmented Th17 differentiation in Trim21 deficiency promotes a stable phenotype of atherosclerotic plaques with high collagen content. Cardiovascular Research, 2018, 114, 158-167.	1.8	57
44	Analysis of B-cell epitopes of the Ro/SS-A autoantigen. Trends in Immunology, 1999, 20, 234-240.	7.5	56
45	High Ro52 Expression in Spontaneous and UV-Induced Cutaneous Inflammation. Journal of Investigative Dermatology, 2009, 129, 2000-2010.	0.3	56
46	In-depth human plasma proteome analysis captures tissue proteins and transfer of protein variants across the placenta. ELife, 2019, 8, .	2.8	56
47	Specificity and effector mechanisms of autoantibodies in congenital heart block. Current Opinion in Immunology, 2006, 18, 690-696.	2.4	55
48	Sex differences in clinical presentation of systemic lupus erythematosus. Biology of Sex Differences, 2019, 10, 60.	1.8	55
49	Epidemiological profile and north–south gradient driving baseline systemic involvement of primary Sj¶gren's syndrome. Rheumatology, 2020, 59, 2350-2359.	0.9	54
50	Genetic associations to germinal centre formation in primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2014, 73, 1253-1258.	0.5	53
51	A serology-based approach combined with clinical examination of 125 Ro/SSA-positive patients to define incidence and prevalence of subacute cutaneous lupus erythematosus. Arthritis and Rheumatism, 2007, 56, 255-264.	6.7	52
52	H1N1 vaccination in Sjögren's syndrome triggers polyclonal B cell activation and promotes autoantibody production. Annals of the Rheumatic Diseases, 2017, 76, 1755-1763.	0.5	51
53	Expression of the Immune Regulator Tripartite-Motif 21 Is Controlled by IFN Regulatory Factors. Journal of Immunology, 2013, 191, 3753-3763.	0.4	49
54	Association between genetic variants in the tumour necrosis factor/lymphotoxin α/lymphotoxin β locus and primary Sjögren's syndrome in Scandinavian samples. Annals of the Rheumatic Diseases, 2012, 71, 981-988.	0.5	47

#	Article	IF	CITATIONS
55	Environmental factors in the pathogenesis of primary Sjögren's syndrome. Journal of Internal Medicine, 2020, 287, 475-492.	2.7	47
56	Association of Genes in the <scp>NF</scp> â€₽B Pathway with Antibodyâ€Positive Primary Sjögren's Syndrome. Scandinavian Journal of Immunology, 2013, 78, 447-454.	1.3	45
57	Anti-Ro52 monoclonal antibodies specific for amino acid 200–239, but not other Ro52 epitopes, induce congenital heart block in a rat model. Annals of the Rheumatic Diseases, 2012, 71, 448-454.	0.5	44
58	Reduced expression of <scp>TRIM</scp> 21/Ro52 predicts poor prognosis in diffuse large B ell lymphoma patients with and without rheumatic disease. Journal of Internal Medicine, 2015, 278, 323-332.	2.7	43
59	A Populationâ€based Investigation of the Autoantibody Profile in Mothers of Children with Atrioventricular Block. Scandinavian Journal of Immunology, 2011, 74, 511-517.	1.3	42
60	Innate immunity and interferons in the pathogenesis of Sjögren's syndrome. Rheumatology, 2021, 60, 2561-2573.	0.9	41
61	Structural, functional and immunologic characterization of folded subdomains in the Ro52 protein targeted in Sjögren's syndrome. Molecular Immunology, 2006, 43, 588-598.	1.0	40
62	Long-term follow-up in primary Sjögren's syndrome reveals differences in clinical presentation between female and male patients. Biology of Sex Differences, 2017, 8, 25.	1.8	39
63	Polymorphisms of the ITGAM Gene Confer Higher Risk of Discoid Cutaneous Than of Systemic Lupus Erythematosus. PLoS ONE, 2010, 5, e14212.	1.1	39
64	lsotype distribution of anti-Ro/SS-A and anti-La/SS-B antibodies in plasma and saliva of patients with Sjögren's syndrome. Scandinavian Journal of Rheumatology, 2000, 29, 13-19.	0.6	38
65	Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus. Scandinavian Journal of Rheumatology, 2002, 31, 133-139.	0.6	37
66	Local production of Ro/SSA and La/SSB autoantibodies in the target organ coincides with high levels of circulating antibodies in sera of patients with Sjögren's syndrome. Scandinavian Journal of Rheumatology, 2003, 32, 79-82.	0.6	37
67	Cutaneous lupus erythematosus: clinical aspects and molecular pathogenesis. Journal of Internal Medicine, 2013, 273, 544-554.	2.7	37
68	Primary Sjögren's syndrometreatment of fetal incomplete atrioventricular block with dexamethasone. Journal of Rheumatology, 2001, 28, 373-6.	1.0	37
69	How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 102-112.	0.4	37
70	Immunoglobulin variable genes and epitope recognition of human monoclonal anti-Ro 52-kd in primary Sjgren's syndrome. Arthritis and Rheumatism, 1999, 42, 2471-2481.	6.7	36
71	Outcome and Growth of Infants Fetally Exposed to Heart Block-Associated Maternal Anti-Ro52/SSA Autoantibodies. Pediatrics, 2008, 121, e803-e809.	1.0	36
72	Brief Report: Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's Syndrome. Arthritis and Rheumatology, 2017, 69, 2187-2192.	2.9	35

#	Article	IF	CITATIONS
73	Doppler echocardiographic and electrocardiographic atrioventricular time intervals in newborn infants: evaluation of techniques for surveillance of fetuses at risk for congenital heart block. Ultrasound in Obstetrics and Gynecology, 2006, 28, 57-62.	0.9	34
74	Benefits of fetal echocardiographic surveillance in pregnancies at risk of congenital heart block: singleâ€center study of 212 antiâ€Ro52â€positive pregnancies. Ultrasound in Obstetrics and Gynecology, 2019, 54, 87-95.	0.9	34
75	Outcome in 212 antiâ€Ro/ <scp>SSA</scp> â€positive pregnancies and populationâ€based incidence of congenital heart block. Acta Obstetricia Et Gynecologica Scandinavica, 2016, 95, 98-105.	1.3	33
76	Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies. Journal of Clinical Investigation, 2015, 125, 4612-4624.	3.9	33
77	Enhanced interferon regulatory factor 3 binding to the interleukinâ€23p19 promoter correlates with enhanced interleukinâ€23 expression in systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 1601-1609.	6.7	32
78	Sex influences eQTL effects of SLE and Sjögren's syndrome-associated genetic polymorphisms. Biology of Sex Differences, 2017, 8, 34.	1.8	32
79	Outcome in young patients with isolated complete atrioventricular block and permanent pacemaker treatment: A nationwide study of 127 patients. Heart Rhythm, 2015, 12, 2278-2284.	0.3	31
80	Infections increase the risk of developing Sjögren's syndrome. Journal of Internal Medicine, 2019, 285, 670-680.	2.7	30
81	Ro/SSA and La/SSB specific IgA autoantibodies in serum of patients with Sjogren's syndrome and systemic lupus erythematosus. Annals of the Rheumatic Diseases, 1999, 58, 623-629.	0.5	29
82	Antiâ€Ro52/SSA antibodyâ€exposed fetuses with prolonged atrioventricular time intervals show signs of decreased cardiac performance. Ultrasound in Obstetrics and Cynecology, 2009, 34, 543-549.	0.9	29
83	Fine specificity of the Ro/SSA autoantibody response in relation to serological and clinical findings in 96 patients with self-reported cutaneous symptoms induced by the sun. Lupus, 2007, 16, 10-17.	0.8	28
84	Serologic follow-up of children born to mothers with Ro/SSA autoantibodies. Lupus, 2009, 18, 792-798.	0.8	28
85	Maternal MHC Regulates Generation of Pathogenic Antibodies and Fetal MHC-Encoded Genes Determine Susceptibility in Congenital Heart Block. Journal of Immunology, 2010, 185, 3574-3582.	0.4	28
86	Ductal epithelial expression of Ro52 correlates with inflammation in salivary glands of patients with primary Sjögren's syndrome. Clinical and Experimental Immunology, 2014, 177, 244-252.	1.1	27
87	Difference in clinical presentation between women and men in incident primary Sjögren's syndrome. Biology of Sex Differences, 2017, 8, 16.	1.8	26
88	The <scp>HLA</scp> locus contains novel foetal susceptibility alleles for congenital heart block with significant paternal influence. Journal of Internal Medicine, 2014, 275, 640-651.	2.7	25
89	The autoantigen Ro52 is an E3 ligase resident in the cytoplasm but enters the nucleus upon cellular exposure to nitric oxide. Experimental Cell Research, 2008, 314, 3605-3613.	1.2	24
90	Childhood-onset of primary Sjögren's syndrome: phenotypic characterization at diagnosis of 158 children. Rheumatology, 2021, 60, 4558-4567.	0.9	24

#	Article	IF	CITATIONS
91	Structurally Derived Mutations Define Congenital Heart Block-Related Epitopes Within the 200-239 Amino Acid Stretch of the Ro52 Protein. Scandinavian Journal of Immunology, 2005, 61, 109-118.	1.3	23
92	The Fellowship of the RING: The RING–B-Box Linker Region Interacts with the RING in TRIM21/Ro52, Contains a Native Autoantigenic Epitope in Sjögren Syndrome, and is an Integral and Conserved Region in TRIM Proteins. Journal of Molecular Biology, 2008, 377, 431-449.	2.0	23
93	The La protein from human liver cells interacts specifically with the U-rich region in the hepatitis C virus 3' untranslated region. Journal of Human Virology, 1999, 2, 296-307.	0.8	23
94	Cloning and characterization of two human Ro52-specific monoclonal autoantibodies directed towards a domain associated with congenital heart block. Journal of Autoimmunity, 2004, 22, 167-177.	3.0	22
95	Structural Organization and Zn2+-dependent Subdomain Interactions Involving Autoantigenic Epitopes in the Ring-B-box-Coiled-coil (RBCC) Region of Ro52. Journal of Biological Chemistry, 2005, 280, 33250-33261.	1.6	22
96	Ro52, Ro60 and La IgG autoantibody levels and Ro52 IgG subclass profiles longitudinally throughout pregnancy in congenital heart block risk pregnancies. Lupus, 2006, 15, 346-353.	0.8	22
97	Diagnostic precision of Doppler flow echocardiography in fetuses at risk for atrioventricular block. Ultrasound in Obstetrics and Gynecology, 2010, 36, 561-566.	0.9	22
98	Potential association of muscarinic receptor 3 gene variants with primary Sjogren's syndrome. Annals of the Rheumatic Diseases, 2011, 70, 1327-1329.	0.5	22
99	Late development of complete atrioventricular block may be immune mediated and congenital in origin. Acta Paediatrica, International Journal of Paediatrics, 2014, 103, 275-281.	0.7	22
100	Concomitant Ro/ <scp>SSA</scp> and La/ <scp>SSB</scp> antibodies are biomarkers for the risk of venous thromboembolism and cerebral infarction in primary Sjögren's syndrome. Journal of Internal Medicine, 2019, 286, 458-468.	2.7	22
101	Clinical Follow-up of 102 Anti-Ro/SSA-positive Patients with Dermatological Manifestations. Acta Dermato-Venereologica, 2008, 88, 370-375.	0.6	22
102	Key residues revealed in a major conformational epitope of the U1-70K protein. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 14487-14492.	3.3	21
103	Minor salivary gland immunohistology in the diagnosis of primary Sjögren's syndrome. Journal of Oral Pathology and Medicine, 2008, 38, 282-288.	1.4	20
104	Neurodevelopment in children with and without congenital heart block born to antiâ€Ro/ <scp>SSA</scp> â€positive mothers. Acta Paediatrica, International Journal of Paediatrics, 2013, 102, 40-46.	0.7	20
105	A possible genetic association with chronic fatigue in primary Sjögren's syndrome: a candidate gene study. Rheumatology International, 2014, 34, 191-197.	1.5	20
106	Comorbidity and long-term outcome in patients with congenital heart block and their siblings exposed to Ro/SSA autoantibodies in utero. Annals of the Rheumatic Diseases, 2019, 78, 696-703.	0.5	20
107	Diminished CXCR5 expression in peripheral blood of patients with SjĶgren's syndrome may relate to both genotype and salivary gland homing. Clinical and Experimental Immunology, 2018, 192, 259-270.	1.1	19
108	The Sjögren's syndrome-associated autoantigen Ro52/TRIM21 modulates follicular B cell homeostasis and immunoglobulin production. Clinical and Experimental Immunology, 2018, 194, 315-326.	1.1	19

#	Article	IF	CITATIONS
109	Ro 52kD autoantibodies are detected in a subset of ANA-negative sera. Scandinavian Journal of Rheumatology, 2000, 29, 116-123.	0.6	18
110	Ro/SS-A- and La/SS-B-reactive B lymphocytes in peripheral blood of patients with Sjögren's syndrome. Clinical and Experimental Immunology, 1999, 115, 208-213.	1.1	17
111	Complement <i>C4</i> Copy Number Variation is Linked to SSA/Ro and SSB/La Autoantibodies in Systemic Inflammatory Autoimmune Diseases. Arthritis and Rheumatology, 2022, 74, 1440-1450.	2.9	17
112	Progression to firstâ€degree heart block in preschool children exposed <i>in utero</i> to maternal antiâ€SSA/Ro52 autoantibodies. Acta Paediatrica, International Journal of Paediatrics, 2012, 101, 488-493.	0.7	16
113	E3 ubiquitin-protein ligase TRIM21-mediated lysine capture by UBE2E1 reveals substrate-targeting mode of a ubiquitin-conjugating E2. Journal of Biological Chemistry, 2019, 294, 11404-11419.	1.6	16
114	Protein and DNA methylation-based scores as surrogate markers for interferon system activation in patients with primary Sjögren's syndrome. RMD Open, 2020, 6, e000995.	1.8	16
115	OUP accepted manuscript. Rheumatology, 2021, 60, 837-848.	0.9	15
116	Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus. Scandinavian Journal of Rheumatology, 2002, 31, 133-9.	0.6	15
117	Autoantibodies to the functionally active RING-domain of Ro52/SSA are associated with disease activity in patients with lupus. Lupus, 2013, 22, 477-485.	0.8	14
118	Viral antigens elicit augmented immune responses in primary Sjögren's syndrome. Rheumatology, 2020, 59, 1651-1661.	0.9	14
119	<scp>TRIM</scp> 21 is important in the early phase of inflammation in the imiquimodâ€induced psoriasisâ€like skin inflammation mouse model. Experimental Dermatology, 2017, 26, 713-720.	1.4	13
120	The rheumatic disease-associated <i>FAM167A-BLK</i> locus encodes DIORA-1, a novel disordered protein expressed highly in bronchial epithelium and alveolar macrophages. Clinical and Experimental Immunology, 2018, 193, 167-177.	1.1	13
121	Type I IFN system activation in newborns exposed to Ro/SSA and La/SSB autoantibodies in utero. RMD Open, 2020, 6, e000989.	1.8	13
122	Doppler echocardiographic isovolumetric time intervals inÂdiagnosis of fetal blocked atrial bigeminy and 2:1 atrioventricular block. Ultrasound in Obstetrics and Gynecology, 2014, 44, 171-175.	0.9	12
123	Proteome study of cutaneous lupus erythematosus (CLE) and dermatomyositis skin lesions reveals IL-16 is differentially upregulated in CLE. Arthritis Research and Therapy, 2021, 23, 132.	1.6	12
124	Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. Rheumatology, 2022, 62, 243-255.	0.9	12
125	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. Clinical and Experimental Rheumatology, 2021, 39, 166-174.	0.4	12
126	Longâ€ŧerm growth of children with autoantibodyâ€mediated congenital heart block. Acta Paediatrica, International Journal of Paediatrics, 2013, 102, 718-726.	0.7	11

#	Article	IF	CITATIONS
127	FoxP3+CXCR5+CD4+ T cell frequencies are increased in peripheral blood of patients with primary Sjögren's syndrome. Clinical and Experimental Immunology, 2019, 195, 305-309.	1.1	9
128	Cigarette smoking patterns preceding primary Sjögren's syndrome. RMD Open, 2020, 6, e001402.	1.8	9
129	Gene-environment interaction in induction of autoimmunity. Seminars in Immunology, 2011, 23, 65-66.	2.7	7
130	Letter to the Editor in response to the article "Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: A review of published literature and registered clinical trials.―by Gleicher N, Elkayam U, Autoimmun Rev. 2013 Sep;12(11):1039-45. Autoimmunity Reviews, 2014, 13, 70-72.	2.5	7
131	Ro/SSA autoantibody-positive pregnancy: reactions to serial fetal Doppler echocardiographic surveillance. Lupus, 2015, 24, 1540-1545.	0.8	7
132	Factors influencing fetal cardiac conduction in anti-Ro/SSA-positive pregnancies. Rheumatology, 2017, 56, 1755-1762.	0.9	7
133	Single-Stranded Oligonucleotide-Mediated Inhibition of Respiratory Syncytial Virus Infection. Frontiers in Immunology, 2020, 11, 580547.	2.2	7
134	The experiences of pregnancy in women with SSA/Ro52 autoantibodies. Musculoskeletal Care, 2010, 8, 215-223.	0.6	6
135	Identification of discrete epitopes of Ro52p200 and association with fetal cardiac conduction system manifestations in a rodent model. Clinical and Experimental Immunology, 2016, 186, 284-291.	1.1	6
136	European families reveal MHC class I and II associations with autoimmune-mediated congenital heart block. Annals of the Rheumatic Diseases, 2018, 77, 1381-1382.	0.5	6
137	Early Resistance of Non-virulent Mycobacterial Infection in C57BL/6 Mice Is Associated With Rapid Up-Regulation of Antimicrobial Cathelicidin Camp. Frontiers in Immunology, 2018, 9, 1939.	2.2	6
138	Surveillance of congenital heart block in highly specialised care. Lancet Rheumatology, The, 2020, 2, e203-e204.	2.2	6
139	Natural killer cells and type II interferon in Ro/SSA and La/SSB autoantibody-exposed newborns at risk of congenital heart block. Annals of the Rheumatic Diseases, 2021, 80, 194-202.	0.5	6
140	Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 97-106.	0.4	6
141	Development of systemic lupus erythematosus in a patient with congenital heart block. Arthritis and Rheumatism, 2003, 48, 2697-2698.	6.7	5
142	Clinical associations and expression pattern of the autoimmunity susceptibility factor DIORA-1 in patients with primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2018, 77, 1840-1842.	0.5	5
143	Increased risk of multiple myeloma in primary Sjögren's syndrome is limited to individuals with Ro/SSA and La/SSB autoantibodies. Annals of the Rheumatic Diseases, 2020, 79, 307-308.	0.5	5
144	Interferons and innate immune activation in autoimmune congenital heart block. Scandinavian Journal of Immunology, 2021, 93, e12995.	1.3	5

#	Article	IF	CITATIONS
145	SOCS3 Expression by Thymic Stromal Cells Is Required for Normal T Cell Development. Frontiers in Immunology, 2021, 12, 642173.	2.2	5
146	Detection of Antigen Specific B-Cells in Tissues. Methods in Molecular Medicine, 2007, 136, 19-24.	0.8	5
147	Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus. Scandinavian Journal of Rheumatology, 2002, 31, 133-139.	0.6	5
148	Response to Comment on "Gene Disruption Study Reveals a Nonredundant Role for TRIM21/Ro52 in NF-IºB-Dependent Cytokine Expression in Fibroblasts― Journal of Immunology, 2009, 183, 7620-7621.	0.4	4
149	Immunological Contribution to the Pathogenesis of Congenital Heart Block. Scandinavian Journal of Immunology, 2010, 72, 171-172.	1.3	4
150	Ro52 autoantibody-positive women's experience of being pregnant and giving birth to a child with congenital heart block. Midwifery, 2013, 29, 18-23.	1.0	4
151	Interferon beta treatment of multiple sclerosis increases serum interleukin-7. Multiple Sclerosis Journal, 2014, 20, 1727-1736.	1.4	4
152	Anti-Ro/SSA autoantibody-positive women's experience of information given on the risk of congenital heart block. Lupus, 2016, 25, 536-542.	0.8	4
153	Environmental and lifestyle factors influencing risk of congenital heart block during pregnancy in anti-Ro/SSA-positive women. RMD Open, 2017, 3, e000520.	1.8	4
154	Pacing therapy in children with isolated complete atrioventricular block: a retrospective study of pacing system survival and pacing-related complications in a national cohort. Europace, 2019, 21, 1717-1724.	0.7	4
155	Interferon activation status underlies higher antibody response to viral antigens in patients with systemic lupus erythematosus receiving no or light treatment. Rheumatology, 2021, 60, 1445-1455.	0.9	4
156	Auxilin is a novel susceptibility gene for congenital heart block which directly impacts fetal heart function. Annals of the Rheumatic Diseases, 2022, 81, 1151-1161.	0.5	3
157	Development of heart block in SSA/SSB autoantibody-positive pregnancies is associated with maternal age and display a season-of-birth pattern. Annals of the Rheumatic Diseases, 2011, 70, A87-A88.	0.5	2
158	TRIM genes are part of the interferon signature observed in patients with primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2012, 71, A81.1-A81.	0.5	2
159	Neonatal Lupus Erythematosus. , 2013, , 464-472.		2
160	Effects of maternal medication on long-term outcome in congenital heart block remain to be established. Response to: â€~Comorbidity and long-term outcome in patients with congenital heart block and their siblings exposed to Ro/SSA autoantibodies in utero' by Satis <i>et al</i> . Annals of the Rheumatic Diseases, 2020, 79, e95-e95.	0.5	2
161	Learning from similarities between vaccine responses and SLE. Nature Reviews Rheumatology, 2020, 16, 355-356.	3.5	2

Killers come to the rescue. Nature Biotechnology, 2002, 20, 1205-1206.

9.4 1

#	Article	IF	CITATIONS
163	Vaccination of patients with primary Sjogren's syndrome reveals hyperreactive B cell compartment with a skewed maturation pattern. Annals of the Rheumatic Diseases, 2011, 70, A67-A67.	0.5	1
164	FRIO419â€Big Data Sjogren Project (Eular-SS Task Force International Network): Systemic Involvement at Diagnosis Evaluated by the Essdai in 3314 Patients with Primary Sjögren Syndrome. Annals of the Rheumatic Diseases, 2015, 74, 578.2-578.	0.5	1
165	Mortality in congenital heart block. Lancet Rheumatology, The, 2020, 2, e588-e589.	2.2	1
166	OC016: Signs of decreased cardiac performance in anti-Ro52/SSA antibody exposed fetuses with prolonged atrioventricular time intervals. Ultrasound in Obstetrics and Gynecology, 2008, 32, 248-248.	0.9	0
167	OR.56. Anti-Ro/SSA Autoantibodies Specific for the RING-domain of Ro52 Inhibit E3 Ligase Activity and Polyubiquitination. Clinical Immunology, 2008, 127, S24.	1.4	0
168	HLA-DRB1*04 is a novel fetal susceptibility allele in congenital heart block. Annals of the Rheumatic Diseases, 2011, 70, A16-A16.	0.5	0
169	Anti-Ro52 epitope mapping in inflammatory myopathies. Annals of the Rheumatic Diseases, 2012, 71, A50.1	0.5	0
170	Neuropsychiatric development and health in children with and without congenital heart block born to mothers with Ro/SSA autoantibodies – a retrospective follow-up. Annals of the Rheumatic Diseases, 2012, 71, A86.1-A86.	0.5	0
171	Identification of novel genetic risk loci determine fetal outcome in congenital heart block. Annals of the Rheumatic Diseases, 2012, 71, A60.2-A60.	0.5	0
172	Ro52 autoantibody-positive women's experience of being pregnant and giving birth to a child with congenital heart block. Annals of the Rheumatic Diseases, 2012, 71, A85-A86.	0.5	0
173	MHC genes determine fetal susceptibility in a rat model of congenital heart block. Annals of the Rheumatic Diseases, 2012, 71, A54.3-A55.	0.5	0
174	3rd Nordic Meeting on Genetics and Pathogenesis of Inflammatory Diseases. Scandinavian Journal of Immunology, 2012, 76, 75-76.	1.3	0
175	A5.27â€Ro52 Expression is a Prognostic Factor for Survival in B Cell Lymphoma. Annals of the Rheumatic Diseases, 2013, 72, A40.2-A40.	0.5	0
176	A7.23â€The HLA Locus Contains Novel Foetal Susceptibility Alleles for Congenital Heart Block with Significant Paternal Influence. Annals of the Rheumatic Diseases, 2013, 72, A56.1-A56.	0.5	0
177	THU0268â€Efficacy and Safety of a Combined Treatment Protocol for 2nd Degree Congenital Heart Block. Annals of the Rheumatic Diseases, 2013, 72, A256.1-A256.	0.5	0
178	SAT0031â€Anti-RO52 autoantibody epitope mapping in european cohort of myositis patients. Annals of the Rheumatic Diseases, 2013, 71, 481.2-481.	0.5	0
179	OP0081â€Identification of a Sjögren's Syndrome-Associated Variant that Influences OAS1 Isoform Switching and Protein Expression. Annals of the Rheumatic Diseases, 2015, 74, 99.2-99.	0.5	0
180	SAT0001â€Identification of Sjögren's Syndrome Risk Loci near TNFAIP3 and PRDM1. Annals of the Rheumatic Diseases, 2016, 75, 664.1-664.	0.5	0

#	Article	IF	CITATIONS
181	SAT0287â€Ethnic Differences Strongly Influence The Phenotypic Expression of Primary Sjögren: Study of 7887 Patients from 20 Countries on 5 Continents (EULAR-SS Task Force Big Data Sjögren Project). Annals of the Rheumatic Diseases, 2016, 75, 772.1-772.	0.5	0
182	THU0352â€Worldwide Heterogeneous Diagnostic Approach To Primary Sjögren Syndrome in 8315 Patients (EULAR-SS Task Force Big Data Sjögren Project). Annals of the Rheumatic Diseases, 2016, 75, 314.2-315.	0.5	0
183	01.15â€Type I IFN system activation in newborns exposed to anti-ro/ssa autoantibodies in utero. , 2017, , .		0
184	THU0280â€Comparison of classification criteria for sjÃ−gren's syndrome from 2002 and 2016 in an incident cohort diagnosed 2007 to 2011 from stockholm county sweden. , 2017, , .		0
185	AB0153â€Functional characterization of the sjögren's syndrome-associated locus ddx6-cxcr5. , 2018, , .		0
186	P014â€FAM167A/BLK is a susceptibility locus in autoimmune diseases: characterisation of the FAM167 gene family. , 2018, , .		0
187	Response to Letter to the Editor by Bartoloni et al: â€~Interplay of anti‣SA/SSB status and hypertension in determining cardiovascular risk in primary Sjögren's syndrome'. Journal of Internal Medicine, 2020, 287, 216-217.	2.7	0
188	O32â€Skin proteome investigation in cutaneous lupus erythematosus (CLE) reveals novel unique disease pathways. , 2020, , .		0
189	Pacing therapy in children with isolated complete atrioventricular block: a retrospective study of pacing system survival and pacing-related complications in a national cohort—Authors' reply. Europace, 2020, 22, 330-331.	0.7	0
190	POS0370â€TYPE I INTERFERON PATHWAY ASSAYS IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES - SYSTEMATIC LITERATURE REVIEW (SLR) AND DEVELOPMENT OF CONSENSUS TERMINOLOGY FROM A EULAR TASKFORCE. Annals of the Rheumatic Diseases, 2021, 80, 415-415.	0.5	0
191	Autoantibodies to the functionally active RING-domain of Ro52/SSA associate with clinical activity in a subset of patients with lupus. Annals of the Rheumatic Diseases, 2012, 71, A40.1-A40.	0.5	0
192	OP0120â€Influence of epidemiology and ethnicity on systemic expression of primary sjÖgren syndrome in 9974 patients. , 2018, , .		0
193	SAT0683â€A north-south worldwide gradient in systemic activity of primary sjÖgren syndrome: increased severe disease in patients from southern countries. , 2018, , .		0
194	OP0139â€FUNCTIONAL EVALUATION OF THE SJÖGREN'S SYNDROME AND SYSTEMIC LUPUS ERYTHEMAT DDX6-CXCR5 RISK INTERVAL. Annals of the Rheumatic Diseases, 2020, 79, 89.1-90.	osys	0
195	THU0224â€SKIN PROTEOME INVESTIGATION IN CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) REVEALS NOVEL UNIQUE DISEASE PATHWAYS. Annals of the Rheumatic Diseases, 2020, 79, 339.2-339.	0.5	0
196	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium Clinical and Experimental Rheumatology, 2021, 39 Suppl 133, 166-174.	0.4	0